Previous close | 64.55 |
Open | 66.48 |
Bid | 65.85 x 100 |
Ask | 66.02 x 300 |
Day's range | 65.46 - 67.07 |
52-week range | 44.20 - 82.04 |
Volume | |
Avg. volume | 742,032 |
Market cap | 7.174B |
Beta (5Y monthly) | 0.89 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
On May 1, 2024, Jim Wassil, the Chief Operating Officer of Vaxcyte Inc (NASDAQ:PCVX), sold 3,000 shares of the company.
Full Year Earnings Reveal Strong Revenue Growth but Operational Challenges Persist
Andrew Guggenhime, President and Chief Financial Officer of Vaxcyte Inc (NASDAQ:PCVX), has sold 8,000 shares of the company on March 18, 2024, according to a recent SEC filing.